Laparoscopic Gastrectomy for Gastric Cancer

Hyuk-Joon Lee  Han-Kwang Yang

Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

Key Words
Laparoscopic surgery · Gastrectomy · Gastric cancer · Review

Abstract
Laparoscopic gastrectomy for gastric cancer is rapidly becoming popular because of the technical developments and the accumulated data of laparoscopic surgery in gastric cancer patients. The aim of this review is to present the current body of evidence and to highlight controversial issues of laparoscopic gastrectomy for gastric cancer. Laparoscopic distal gastrectomy (LDG) provides better or comparable outcomes compared to conventional open distal gastrectomy (ODG) in terms of short-term results. The long-term survival of LDG is expected to be comparable to that of ODG in early-stage gastric cancer, and an ongoing Korean multicenter randomized controlled trial (KLASS-01) will provide more clear evidence. Laparoscopic total gastrectomy is still selectively performed compared to LDG, and there is still debate on the safety of the laparoscopic esophagojejunostomy technique. Laparoscopic pylorus-preserving gastrectomy seems to be preferred for early gastric cancer in the middle third of the stomach in terms of functional advantages and comparable oncologic outcome. Evidence for LDG for advanced gastric cancer is still insufficient and the issue of lack of generalization still remains, even after ongoing multicenter randomized controlled trials have revealed clinical evidence. Laparoscopic sentinel node navigation surgery is still experimental and the surgical procedure has yet to be standardized. Robotic gastrectomy is feasible for early gastric cancer in terms of similar outcome, but is much more expensive in comparison to laparoscopic surgery. Its benefit over the conventional laparoscopic gastrectomy has not yet been proven.

Introduction

After the initial introduction of laparoscopic gastrectomy for gastric cancer by Kitano et al. [1] in 1993, the procedure has spread rapidly and is now considered one of the standard minimally invasive procedures for the treatment of early gastric cancer (EGC). In Korea, for example, the number of laparoscopic surgeries for gastric cancer increased from 740 in 2004 to 3,783 in 2009, rising from 6.6% of all gastric cancer surgeries to 25.8%, respectively [2]. The cumulative number of laparoscopic gastric cancer surgeries from 1995 to 2009 was estimated to be 14,731 in Korea [3]. Along with laparoscopic gastrectomy, other laparoscopic gastric surgeries such as wedge resection or peptic ulcer surgery has also increased (fig. 1).

Over last two decades, laparoscopic gastrectomy has provided a lot of clinical evidence, mainly from Korea and Japan, and today some experts have extended their use of laparoscopic gastrectomy from EGC to advanced gastric...
For the indication of laparoscopic gastrectomy, gastric adenocarcinoma is commonly indicated; however, benign gastric ulcer or gastric subepithelial tumor is sometimes indicated, too. The extent of lymph node (LN) dissection is an important issue. In general, most articles report D1 + α, D1 + β, or D2 dissection, which means at least a D1 + LN dissection according to the 3rd Japanese Gastric Cancer Treatment Guidelines [4].

Laparoscopic gastrectomy can be classified into laparoscopic distal gastrectomy (DG), total gastrectomy, pylorus-preserving gastrectomy (PPG), and proximal gastrectomy in terms of the resection extent of the stomach. From the perspective of the surgical approach, it can be also classified into laparoscopy-assisted gastrectomy (LAG) and totally laparoscopic gastrectomy. LAG means parts of the surgical procedures (usually anastomosis) are performed outside the body (extracorporeal) through minilaparotomy. In contrast, totally laparoscopic gastrectomy means all parts are performed inside the body (intracorporeal) by a laparoscopic approach (i.e. intracorporeal anastomosis). Combining these two criteria, dozens of terms are used in the literature, such as laparoscopy-assisted distal gastrectomy (LADG), laparoscopy-assisted total gastrectomy (LATG), (totally) laparoscopic distal gastrectomy (TLDG or LDG), etc. [3]. However, this terminology sometimes overlaps, for example the term ‘LADG’ is sometimes used for indicating both LADG and TLDG.

In this review, we will present the current clinical data of the different types of laparoscopic gastrectomy in terms of short- and long-term outcomes, with special reference to the extent of resection and indication of surgery. In addition, we will discuss several controversies surrounding laparoscopic gastrectomy and highlight what is still required in the field of laparoscopic gastrectomy for gastric cancer. Finally, laparoscopic sentinel node (SN) navigation surgery and robotic gastrectomy will be discussed. Laparoscopic wedge resection, sometimes included in laparoscopic gastrectomy, will not be covered in this article.

**Methods**

A PubMed search was carried out using the search terms ‘laparoscopic gastrectomy’ AND ‘gastric cancer’ along with their synonyms or abbreviations until February 2013. Meta-analyses and randomized controlled trials (RCT) were firstly reviewed, and the references of the each identified articles were also evaluated. Large-scale prospective cohort studies, retrospective case-control studies, and case series were also reviewed. Selected ongoing clinical trials in which the clinical influence seems to be high were also included.

**Laparoscopic Distal Gastrectomy**

LDG or LADG is the first and most commonly performed laparoscopic gastrectomy for gastric cancer. Nowadays, the general indication is considered as EGC.
located in the middle or lower third of the stomach. Three types of reconstruction are usually performed: gastroduodenostomy (Billroth I), loop gastrojejunostomy (Billroth II), and Roux-en-Y gastrojejunostomy.

Most surgeons use 5 or 6 trocars in a similar location for LADG. As usual, the range of LN dissection covers Nos. 1, 3, 4sb, 4d, 5, 6, 7, 8a, 9, and 11p with or without Nos. 12a and 14v according to the Japanese gastric cancer classification [5]. For the anastomosis, a circular or linear stapler is commonly used through a 4- to 5-cm vertical or transverse minilaparotomy on the upper abdomen in case of extracorporeal gastroduodenostomy or gastrojejunostomy [6]. In case of intracorporeal anastomosis, a delta-shaped anastomosis is commonly applied for the gastroduodenostomy [7]. Although intracorporeal anastomosis has some advantages, such as providing a better operative view and a wider range for movement during the reconstruction (especially for obese patients), it is still controversial to use routinely because of its higher cost for more staples and similar clinical outcomes compared with extracorporeal anastomosis [8].

Several meta-analyses focusing on LADG in comparison to open distal gastrectomy (ODG) have been published. Among them, Zeng et al. [9] performed a meta-analysis including 5 RCTs and 18 non-RCTs with 3,411 patients, and reported that LADG may reduce intraoperative blood loss, overall postoperative morbidity, postoperative analgesic consumption, and hospital duration without increasing the total hospitalization costs and cancer recurrence rate. They also reported that the mean number of retrieved LNs and overall survival rate were comparable between the LADG and ODG groups. Similarly, Strong and colleagues [10] reported that LADG can be performed safely with a shorter hospital stay and fewer complications than open surgery in a meta-analysis with 6 RCTs and 19 non-RCTs with 3,055 patients. In addition, Jiang et al. [11] recently made another meta-analysis including 8 RCTs (n = 784 patients) only and reported that LADG has the advantage of better short-term outcome compared to ODG.

At least six important RCTs comparing LADG versus ODG have been published in the English literature [12–17] (table 1). Five of these trials were from Japan or Korea, and only one was from a Western country (Italy). The number of patients enrolled in each trial ranged from 28 to 342. The three reports from Korea [15–17] used adequate random allocation sequences; however, the exact method of randomization was unclear in the other trials, which only stated that allocation had been 'randomized' [11]. Except for the RCT from Italy [14], the trials from the East included only clinically EGC or stage I disease. Only one RCT [17] was conducted as a multicenter trial in a single country, and to date, there have been no multinational trials. The long-term survival difference was not available because of insufficient follow-up time or small sample size in these RCTs.

Among the RCTs, the largest and most noticeable one is the Korean multicenter trial named KLASS (Korean Laparoendoscopic Gastrointestinal Surgery Study; NCT00452751). The indication was clinical stage I (cT1N0M0, cT1N1M0, and cT2N0M0) gastric adenocarcinoma. The primary endpoint was overall survival, and the secondary endpoints were disease-free survival, morbidity, mortality, quality of life, inflammatory and immune responses, and cost-effectiveness. A distal gastrectomy with D1 + β or D2 LN dissection was performed in both groups. Reconstruction was performed by Billroth I or Billroth II or Roux-en-Y fashion, depending on the surgeons’ preference. To assure high surgical quality, surgery was performed by 15 surgeons, who had performed

<table>
<thead>
<tr>
<th>Author</th>
<th>Country</th>
<th>Study period</th>
<th>Sample size (L/O)</th>
<th>LND</th>
<th>Reconstruction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kitano et al.</td>
<td>Japan</td>
<td>1998–2001</td>
<td>14/14</td>
<td>D1 + α</td>
<td>B-I</td>
</tr>
<tr>
<td>Hayashi et al.</td>
<td>Japan</td>
<td>1999–2001</td>
<td>14/14</td>
<td>D1 + α</td>
<td>B-I</td>
</tr>
<tr>
<td>Huscher et al.</td>
<td>Italy</td>
<td>1992–1996</td>
<td>30/29</td>
<td>D1 or D2</td>
<td>B-II or RY</td>
</tr>
<tr>
<td>Lee et al.</td>
<td>Korea</td>
<td>2001–2003</td>
<td>24/23</td>
<td>D2</td>
<td>B-I</td>
</tr>
<tr>
<td>Kim et al.</td>
<td>Korea</td>
<td>2003–2005</td>
<td>82/82</td>
<td>D1 + β or D2</td>
<td>B-I</td>
</tr>
<tr>
<td>Kim et al.</td>
<td>Korea</td>
<td>2006–2007</td>
<td>179/163</td>
<td>D1 + β or D2</td>
<td>B-I (mainly)</td>
</tr>
</tbody>
</table>

L = Laparoscopic; O = open; LND = lymph node dissection; B-I = Billroth-I gastroduodenostomy; B-II = Billroth-II gastrojejunostomy; RY = Roux-en-Y gastrojejunostomy.
at least 50 cases each of LADG and ODG, at 12 institutes, which had performed more than 80 cases of distal gastrectomy per year. The initial sample size was 1,400. From February 2006 to August 2010, 1,415 patients (704 LADG and 711 ODG) were enrolled, and the final results are expected to be reported in September 2015 [18].

The interim analysis of this KLASS-01 trial was published in 2010. A total of 342 patients were randomized (179 LADG and 161 ODG). There were no significant differences between the two groups concerning patient demographics. The postoperative complication rates of LADG and ODG groups were 10.5% (17/179) and 14.7% (24/163, p = 0.137). The postoperative mortality was 1.1% (2/179) and 0% (0/163) in the LADG and ODG groups (p = 0.497). The authors concluded that there was no significance difference in the morbidity and mortality between the two groups [17].

Another important Korean single-center RCT, conducted by Kim et al. [16], was published in 2008. This study aimed to evaluate the quality of life after LADG compared to ODG (n = 82 in each group) in patients with EGC. The LADG group showed better functional and symptom scales of EORCT QLQ-C30 and QLQ-ST022 at 3 months after surgery. Also, intraoperative blood loss, total amount of postoperative analgesics, and postoperative hospital stay were significantly less in the LADG group. The authors concluded that LADG resulted in improved quality of life outcomes after surgery in EGC patients compared to ODG.

The RCT from Italy was published by Huscher et al. [21] in 2005. This study was unique in terms of inclusion of advanced cancer as well as reporting survival data. Among the 59 patients enrolled, 37 (63%) were finally revealed as stage II or more. Operative morbidity and mortality rates were 26.7 and 3.3% in LADG group and 27.6 and 6.7% in the ODG group, respectively. Five-year overall survival rates were 58.9 and 55.7% in the LADG and ODG groups. Although the authors concluded that LADG for distal gastric cancer is a feasible and safe oncologic procedure, there was a lot of criticism concerning this trial, including the small number of patients, enrollment of diverse stages, surgical quality, and lack of background data for the inclusion of AGC.

Recently, the Japanese Clinical Oncology Group (JCOG) launched an RCT comparing LADG versus ODG for clinical stage I gastric cancer. This trial (JCOG 0912, UMIN000003319) plans to enroll 920 patients within 5 years. The primary endpoint is overall survival, and the secondary endpoints are relapse-free survival, conversion rate of LADG group, short-term clinical outcomes, and postoperative quality of life [19]. Therefore, the study design of the JCOG 0912 trial is basically the same as the KLASS trial, and these two trials should provide solid evidence for the role of LADG in patients with stage I gastric cancer.

For the long-term outcome of LADG, many case-control studies and case series are currently available [20–23]. The Japanese Laparoscopic Surgery Study Group (JLSSG) reported a retrospective multicenter study of laparoscopic gastrectomy for EGC in 2007. Analyzing 1,294 patients from 16 hospitals from 1994 to 2003, they showed that only 6 (0.6%) patients had a recurrence during a median follow-up of 36 months (range: 13–113), and the 5-year disease-free survival rate was 99.8% for stage Ia, 98.7% for stage Ib, and 85.7% for stage II disease. In this cohort, LADG was performed in 1,185 patients (91.5%), and the 5-year disease-free survival after LADG was 99.4% [20].

The KLASS Group also reported a similar retrospective multicenter long-term outcome of 1,417 patients who underwent LAG at 10 hospitals from 1998 to 2005. LADG was performed for 1,263 patients (89.1%). Recurrence was observed in 1.6% (19/1,186) in EGC and 13.4% (31/231) in AGC during 41 months of median follow-up (range: 2–109). Recurrence time and pattern was similar to that of conventional open surgery. Thirty-four patients out of 50 (68.0%) had a recurrence within 2 years after surgery, and the recurrence pattern was hematogenous in 17 (34.0%), peritoneal in 11 (22.0%), locoregional in 10 (20.0%), distant LNs in 2 (4.0%), and mixed in 10 (20.0%) [21].

Strong et al. [22] at Memorial Sloan-Kettering Cancer Center in New York reported a retrospective case-control study comparing 30 LADG with 30 ODG. Controls were matched for stage, age, and gender from 2005 to 2008. The mean number of resected LNs was 18 (range: 7–36) in the LADG group and 21 (range: 7–44) in the ODG group (p = 0.03). There were 4 recurrences (13.3%) in the LADG group during 11 months of follow-up and 5 recurrences (16.6%) in the ODG group during 13.8 months follow-up (p = 0.71). Our group did a similar retrospective case-control study in which the clinical outcomes of EGC patients who underwent LADG (n = 100) and sex-, age-, and BMI-matched EGC patients who underwent ODG (n = 100) were compared retrospectively. Although the mean number of resected LNs were smaller in the LADG group compared to the ODG group (29.3 vs. 36.4, p < 0.001), the recurrence rate was not different between the two groups (2% in LADG vs. 1% in ODG) with no cancer-related deaths for 40 months for LADG and 35 months for ODG [23].

Laparoscopic Gastrectomy
**Laparoscopic Total Gastrectomy**

Unlike LADG, laparoscopic total gastrectomy (LTG) or LATG remains a challenging procedure and the technique has not yet been standardized [24]. The general indication is EGC located in the upper third of the stomach. However, compared to LADG, LATG seems to be selectively performed, even in Korea and Japan. In Korea, for example, 25.3% (2,354/9,290 patients) of middle or lower third gastric cancer was treated by laparoscopy, but only 7.5% (231/3,062 patients) of upper third gastric cancer was treated by laparoscopy in 2009 [25].

Trocar placement is similar to LADG; however, many surgeons prefer to place right 2 trocars more medially in LATG for the efficient removal of LNs around the splenic hilum (No. 10), LNs along distal splenic artery (No. 11d), and left paracardial LNs (No. 2).

Esophagojejunostomy is usually made by Roux-en-Y, either with an extracorporeal or intracorporeal approach [3]. Extracorporeal anastomosis is performed through a 4- to 5-cm vertical minilaparotomy incision made on the upper midline. After placing the anvil head into the distal esophagus, the mesentry of the proximal jejunum which was pulled out through the minilaparotomy is divided to make a Roux limb. Thereafter, jejunojejunostomy is made either manually or by a stapler, and finally esophageojjunostomy is performed by a circular stapler. Sometimes, it is difficult to obtain a sufficient proximal resection margin in obese patients or tumors located near the esophagogastric junction, and it is also difficult to get enough length of the Roux limb which is partially exposed through the minilaparotomy site. To overcome these limitations, several types of intracorporeal anastomoses have been developed over the last several years [26].

Transoral introduction of the anvil head of the circular stapler (OrVil) is one of the most promising methods. Sakuramoto et al. [27] reported that intracorporeal esophagojejunostomy with this technique was achieved successfully in 26 out of 27 patients. No other complications, such as hypopypongeal or esophageal injury, occurred during passage, and no postoperative complications occurred except one anastomotic stenosis. On the other hand, Nagai et al. [28] reported a case series of 94 patients who underwent intracorporeal esophageojjunostomy with a linear stapler. Only 2 cases of anastomotic leakage were developed after surgery, but there was no open conversion or mortality in this cohort.

Recently, a meta-analysis [29] was reported including eight non-RTCs with 314 LTG and 384 open total gastrectomy (OTG) in patients with gastric cancer. LTG showed less intraoperative blood loss, less postoperative complications, and shorter hospital stay compared with OTG, although operation time was longer in the LTG group. In-hospital mortality rates were comparable for LTG (0.9%) and OTG (1.8%). The authors concluded that LTG shows better short-term outcomes compared with OTG in patients with gastric cancer. Among eight studies enrolled in this meta-analysis, Kim et al. [30] reported the largest retrospective case-control study in which 73 LTG and 127 OTG were compared. D1+ or D2 LN dissection was performed, and the esophagojejunostomy was in an extracorporeal manner. There were no significant differences in postoperative complication rates. However, LATG could improve time to first flatus, time to commencement of soft diet, administration of analgesics, pain score, and hospital discharge. The KLASS Group also reported a retrospective multicenter cohort study with 131 patients who underwent LATG. Only one patient required conversion to open procedure. The mean number of retrieved LNs was 34.7. The mean duration of postoperative hospital stay was 11.3 days, and the postoperative morbidity rate was 19% without operative mortality. The most common postoperative morbidity was wound complications at the minilaparotomy site, and there were 3 cases of anastomotic leakage. Six patients (5%) had recurrence of cancer, and 9 patients (7%) died during the follow-up period [31].

All of these retrospective data show the safety and effectiveness of LATG; however, a multicenter RCT or prospective cohort study is required to rule out the possibility of publication bias. In Korea, a multicenter single-arm phase II trial evaluating LATG for stage I gastric cancer (KLASS-03) has just been launched. The total number of patients is expected to be 168, and postoperative 30-day morbidity and mortality will be primarily measured. The method for anastomosis is not unified and can be determined by the surgeon’s preference. To our knowledge, this trial may be the first multicenter trial evaluating LATG in the world, and the final result will reveal the safety issue of LATG in general practice.

**Laparoscopic PPG**

According to the Japanese gastric cancer treatment guidelines, PPG can be used for cT1NO gastric cancer in the middle portion of the stomach with the distal tumor border at least 4 cm proximal to the pylorus [4]. Therefore, either DG or PPG can be performed to treat middle third EGC. Compared to DG, PPG has several advantages such as nutritional benefit and lower incidence of...
dumping syndrome, bile reflux, and gallstone formation [32, 33]. Recently, clinical data has been reported that validate the role of PPG done by laparoscopy.

PPG is different from DG in terms of the preservation of the distal antrum (about 3 cm), hepatic branch of vagus nerve, right gastric vessel, and infrapyloric vessel. For the LN dissection, the No. 5 and 12a stations remain left and the No. 6 station is partly limited. Gastrogastrostomy is mostly created in an end-to-end manner. In the laparoscopic procedure, it is usually performed using an extracorporeal hand-sewn method since the antrum is too thick to be cut and anastomosed by a linear stapler.

Recently, Hiki and colleagues [34] reported the short-term outcomes of 307 patients who underwent laparoscopy-assisted pylorus-preserving gastrectomy (LAPPG) from 2005 to 2009. The mean operation time for LAPPG was 229.4 min and estimated blood loss was 49.1 ml. The mean number of dissected LNs was 31.6. Complications developed in 53 patients (17.3%), and major complications (grade IIIa or higher according to the Clavien-Dindo classification [35]) were observed in only 4 patients (1.3%). The most frequent complication was gastric stasis, occurring in 19 patients (6.2%). Body mass index (BMI) was related to the severity of the complications.

Our group performed a retrospective analysis comparing those who underwent LAPPG (n = 116) and LADG (n = 176) for middle third EGC. The overall postoperative morbidity rate was similar between the two groups, although delayed gastric emptying was more frequent in LAPPG than in LADG (7.8 vs. 1.7%). The number of retrieved LNs was not significantly different (35.9 in LAPPG vs. 35.2 in LADG), and 3-year recurrence-free survival rates were also similar between LAPPG and LADG (98.2 vs. 98.8%). Serum protein and albumin at postoperative 1 and 6 months as well as abdominal fat area measured by CT scan at postoperative 1 year were significantly less decreased in LAPPG. The 3-year cumulative incidence of gallstone was also significantly lower in LAPPG than in LADG (0 vs. 6.5%) [36]. Therefore, LAPPG can be considered as a better treatment option than LADG in terms of nutritional advantage and lower incidence of gallstone for middle third EGC.

**Risk Factors for Postoperative Morbidity in Laparoscopic Gastrectomy**

Risk factors for postoperative morbidity in laparoscopic gastrectomy may not differ so much from those in open gastrectomy. Three aspects may be considered for the prediction of complication: tumor-related factors, patient-related factors, and surgeon-related factors.

Before starting the KLASS trial, the Korean surgeons had collected large-scale retrospective multicenter data from each participating surgeon’s beginning to the end of 2005 to reveal the safety profile and the risk factors for operative morbidity in laparoscopic gastrectomy. The data of 1,485 patients who underwent LAG for gastric cancer with more than D1 LN dissection by 10 surgeons were analyzed. Overall morbidity and mortality rates were 14.0 and 0.6%, respectively. Complications included wound problems (4.2%, n = 62), intraluminal bleeding (1.3%, n = 20), intra-abdominal abscess or fluid collection (1.3%, n = 19), anastomotic leakage (1.3%, n = 18), and intra-abdominal bleeding (1.3%, n = 18). Sex, comorbidity, type of resection, and surgeon’s experience were found to be independent risk factors for local complications, and age was found as an independent risk factor for systemic complication [37]. Furthermore, among various comorbidities of the patients, pulmonary comorbidity was shown to be related with most types of immediate postoperative complications compared with other comorbidities [38].

The KLASS group also performed several comparative studies in terms of several interesting potential risk factors for complication, such as age, obesity, surgeon’s inexperience, etc. In terms of age, laparoscopic surgery is generally regarded as offering a substantial advantage to old patients in terms of fewer cardiorespiratory complications, shorter hospital stay, and faster return to physical activities [39]. Cho et al. [40] reported that patients aged 70 years or more (n = 226) did not show significant differences in postoperative morbidity or mortality, compared to patients aged 45–69 years (n = 890). Preoperative comorbidity was revealed as the only risk factor for postoperative complications in this elderly group.

Obesity is known to be one of the risk factors for postoperative morbidity [41]. However, there are conflicting reports suggesting that obesity may or may not increase operative morbidity following laparoscopic gastrectomy [42, 43]. Lee et al. [44] compared clinical outcomes between high BMI (≥25, n = 432) and low BMI (<25, n = 1,053). Postoperative morbidity and mortality did not differ between the high BMI (15.7 and 0.9%) and low BMI (14 and 0.5%) groups. Only the operation time and the number of retrieved LNs were significantly different between the high BMI (242.5 min and 30.4) and low BMI (223.7 min and 32.6) groups, especially for male patients undergoing surgery by surgeons who had performed 40 or fewer LAGs. The authors concluded that although high
BMI itself did not increase operative morbidity, a careful approach is required for male patients with high BMI when a surgeon is relatively inexperienced with LAG.

**Laparoscopic Gastrectomy for Advanced Cancer**

As surgical experience increases, some surgeons are now applying laparoscopic gastrectomy with D2 LN dissection for patients with AGC. There have been reports of short-term outcomes with morbidity rates of 11.3–15.9% and mortality rates of 0.8–2.2%, which are comparable to those of open surgery [2].

A recent meta-analysis, including seven case-control studies with 1,271 AGC patients (626 LADG and 645 ODG), showed that LADG patients had longer operative time but less estimated blood loss, less analgesic requirement, and a shorter hospital stay compared with patients undergoing ODG. There were no significant differences between the two groups in number of LN dissections, postoperative mortality, overall complications, and 3-year overall survival rate. Therefore, the authors concluded that the oncologic outcomes of LADG for AGC patients were comparable with an open approach [45].

Kim and colleagues [46] reported the short-term outcomes of a prospective single-arm phase II trial evaluating the feasibility of laparoscopic gastrectomy for patients with cT2N0–cT4aN2 gastric cancer (NCT01441336). Of the 157 patients enrolled, conversion to open surgery occurred in 11 patients (7.0%). The mean number of retrieved LNs was 52.7 for distal gastrectomy and 63.8 for total gastrectomy. The total complication rate was 25.5% as a whole, and the local and systemic complication rates of grade II or higher according to the Clavien-Dindo classification were 8.3 and 3.2%. One patient died of operative complications. They concluded that laparoscopic gastrectomy with D2 LN dissection was safe and technically feasible for the treatment of AGC, with an acceptable rate of morbidity and mortality.

Along with these background data of LADG on AGC, another KLASS trial evaluating the efficacy of LADG with D2 LN dissection for cT2-T4a gastric cancer (KLASS-02-RCT) was launched in October 2011 (NCT01456598). The estimated sample size is 1,050 and the primary endpoint is 3-year disease-free survival rate (NCT01441336). Of which 90 are to be treated with the laparoscopic approach, the incidence of major surgical complications will be assessed. If an early-stopping rule because of high incidence of complications does not apply, the trial will continue accrual for a total of 500 patients to show non-inferiority of the laparoscopic approach [24]. These two Korean and Japanese clinical trials are expected to reveal the role of laparoscopic surgery for AGC, although the generalization issue will still remain.

**Laparoscopic SN Node Navigation Surgery**

Several experimental studies have shown that SN biopsy with radioisotope and/or visible dye could be feasible for EGC in open and laparoscopic surgery [47–49]. However, because of unsatisfactory sensitivity and heterogeneity of SN biopsy among practicing surgeons, the concern and limitation about its clinical application still exists.

A recent meta-analysis evaluating 38 studies with 2,128 patients showed that the pooled SN identification rate, sensitivity, negative predictive value, and accuracy were 93.7, 76.9, 90.3, and 92.0%, respectively. Subgroup analysis showed that early T stage, combined tracers, submucosal injection method, conventional open surgery, and usage of immunohistochemistry were associated with a higher SN identification rate and sensitivity. Focusing on surgical procedure, SN identification rate, sensitivity, false-negative rate, and accuracy in the laparoscopic group (11 studies) and open group (29 studies) were 89.3 vs. 95.0%, 68.6 vs. 78.3%, 31.4 vs. 21.7%, and 92.6 vs. 91.9%, respectively [50].

Therefore, considering its fatal outcome of false-negative results on SN navigation surgery for the patients with EGC, further studies are needed to confirm the best procedure and standard criteria, especially in laparoscopic surgery [51].
Robot-assisted surgery is laparoscopic surgery using robotic instruments. Compared to the laparoscopic surgery, robotic surgery may have some benefits such as three-dimensional imaging, increased degree of freedom, a steady camera platform, and the filtration of resting tremor. Several reports about robotic surgery for gastric cancer have been reported, mainly from institutes in Korea [52, 53]. These reports suggest comparable short-term morbidity and oncologic outcomes compared with laparoscopic gastrectomy. However, the concrete advantage of robotic surgery for the patient still remains elusive in terms of the similar number of trocars used, longer operation time, negligible difference in blood loss, and much higher cost, even though robotic instruments may provide some benefit of dexterity which has not been proven scientifically [54, 55], especially the ultrasonic shears which do not articulate. Furthermore, there is an energy device in development with roticulating function which may provide an advantage in more demanding tissue dissection at splenic artery or splenic hilum.

To explore the role of robotic gastrectomy for gastric cancer, the Korean Robot Gastrectomy Study Group of KLASS started in 2010 to conduct a multicenter prospective, case-matched clinical trial comparing robotic versus laparoscopic gastrectomy for EGC. Enrollment of 400 patients (200 in each group) was finished in 2012, and surgical complications, quality of life, immunologic response, and cost-effectiveness will be analyzed.
Laparoscopic gastrectomy is a promising minimally invasive surgery for gastric cancer that has become popular and standardized. LADG shows better or comparable outcomes compared to ODG in terms of short-term results. The long-term outcome after LADG may be comparable to ODG in EGC, and ongoing Korean and Japanese multicenter RCTs will provide more clear evidence. Data on LATG are still limited, and the stable laparoscopic anastomosis technique is still under debate. LAPPG seems to be optimistic for EGC located in the middle third of the stomach in terms of preservation of function and comparable oncologic outcome.

The clinical body of evidence concerning LADG for AGC is still insufficient, and the lack of generalization still remains an issue even after ongoing Korean multicenter RCTs have provided clinical evidence. Laparoscopic SN navigation surgery seems to be experimental and the surgical procedure has yet to be standardized. Robotic gastrectomy is feasible for EGC in terms of similar outcome, but is associated with much higher cost compared to laparoscopic surgery. Its benefit over the conventional laparoscopic gastrectomy has not been proven.

References


